相关实验视频

Updated: May 6, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

与新辅助疗法不敏感性相关的因素及其在HER2阳性乳腺癌的预后影响

Yuhang Han¹, Bo Lan¹, Zexi Peng¹

¹Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

|January 12, 2026

概括

在HER2+乳腺癌中,新辅助疗法 (NAT) 的不敏感性与激素受体状态和HER2状态有关,表明无事件生存率较差. 需要对HER2异质性的进一步研究.

科学领域:

在瘤学瘤学.
乳腺癌研究研究乳腺癌研究
分子诊断学分子诊断

背景情况:

一部分HER2+乳腺癌患者对新辅助疗法 (NAT) 呈现内在耐药性.
由稳定或渐进的疾病表明的NAT不敏感性,需要对相关因素和预后影响进行调查.

研究的目的:

为了确定与HER2+乳腺癌中NAT不敏感性相关的因素.
为了评估这种患者群体中NAT不敏感性的预后值.

主要方法:

541名接受NAT (化疗+抗HER2抗体) 的HER2+乳腺癌患者的回顾性分析.
被定义为稳定疾病 (SD) 或进展性疾病 (PD) 的NAT不敏感性.
临床数据的统计分析和HER2异质性的评估.

主要成果:

11.6%的患者对NAT不敏感.
与激素受体 (HR) 状态,HER2 状态和抗HER2 治疗相关的 NAT 不敏感性 (P<0.05).
对NAT不敏感组的无事件生存期 (EFS) 显著较短 (3年:69.4% vs. 94.3%,P<0.001),是独立的预后因素 (HR=8.637,P<0.001).
在NAT不敏感组中观察到更高的HER2异质性 (19.4%对4.3%,P=0.035).

结论:

激素受体阳性,HER2 2+/FISH+状态,和特拉斯图祖马布单一治疗与NAT不敏感性相关.
NAT不敏感性是HER2+乳腺癌中EFS差的重要独立预测因素.
有必要进行前性研究,以探索HER2异质性和其他机制在预测NAT反应中的作用.

关键词:

HER2异质性 HER2的异质性在HER2阳性乳腺癌中,HER2是阳性乳腺癌.不敏感性不敏感性进行抗HER2治疗.新辅助疗法是一种新辅助疗法.

更多相关视频

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...